History

2023
  • NOV

    Participated and advertised company’s assets in the 2023 BIO-Europe conference

  • NOV

    Presented a poster describing preclinical studies of TXN10128 at the 2023 SITC annual conference in San Diego

  • OCT

    Closed second Series B funding round
    (Korea Venture Investment Corp, Well to Sea, IBK, Woori Bank, Woori Financial Capital, Hyundai Pharm, C&R Research)

  • OCT

    Awarded Korea Drug Development Fund grant for clinical development of ENPP1 inhibitor

  • SEP

    First patient received first dose of TXN10128

  • AUG

    Successfully completed KDDF grant for preclinical development of ENPP1 inhibitor in advance of completion date

  • JUL

    Officially opened phase I clinical trial of TXN10128 at Asan medical center in Seoul

  • JUN

    Participated and advertised company’s assets in the 2023 BIO international convention

  • MAY

    Awarded Global company support program grant to acquire a molecular modeling system (Ministry of SMEs and Startups)

  • MAY

    Applied IND for clinical development of TXN10128 was approved.

  • MAR

    Completed IND submission for clinical development of ENPP1 inhibitor, TXN10128.

  • JAN

    Signed the agreement of strategic investment with Hyundai pharmaceuticals and started collaboration for novel drug development.

  • JAN

    Selected as a company receiving matching fund from Korean venture investment

2022
  • DEC

    Closed first part of series B funding
    (Korea investment Partners, Company K investment,
    Solidus investment, Daily Partners,
    Meditox venture investment)

  • DEC

    Successfully completed Tech Incubator Program
    for Startup korea grant

  • DEC

    Launched a collaboration with HK inno.N
    for novel drug development

  • AUG

    Exchanged MOU with K-MEDI Hub

  • AUG

    Exchanged MOU with Ahngook Pharm.

  • JUN

    Awarded Korea Drug Development Fund grant
    for ENPP1 inhibitor

  • JUN

    Awarded ministry of science
    and information communication grant

  • JUN

    Participated in the 2022 BIOUSA conference

  • MAY

    Awarded bioresearch data generation support grant

  • APR

    Awarded AI voucher support grant for ULK1 inhibitor

  • MAR

    Awarded Korea Drug Development Fund grant
    for ULK1 inhibitor

  • MAR

    Opened animal facility (named “spleen”)

  • JAN

    Exchanged MOU with AnaPath for pre-clinical development

2021
  • OCT

    Participated in the 2021 BIO-EUROPE ®

  • OCT

    Presented poster
    at the 2021 AACR-NCI-EORTC annual conference

  • SEP

    Exchanged MOU with HK Inno.N Corp.

  • AUG

    Completed Series A funding round
    (Korea Investment Partners, Schmidt,
    DSC investment, Company K investment)

  • MAY

    Closed 2nd angel funding round

  • JAN

    Opened headquarter and R&D center at Gwanggyo

  • JAN

    Certified as a corporate affiliated research institute

2020
  • NOV

    Certified as a venture business corporation

  • OCT

    Awarded Tech Incubator Program
    for Startup Korea (TIPS) grant.

  • OCT

    Completed Pre-A funding round
    (Korea Investment Partners, Schmidt, DSC investment)

  • SEP

    Closed 1ST angel funding round

  • SEP

    Launched Txinno Bioscience inc.

2018
  • MAR

    Started as Incubator Team #2 of BioStar project at KIST